Columbia Healthcare

Business Insights

Aculys Pharma, Inc. | July 13, 2022

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

LabRoots | January 20, 2020

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Pharmacy Market

Xeris Pharmaceuticals, Inc. | September 01, 2021

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatmen...

Labiotech.eu | February 21, 2020

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...